The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results